Combined Pim and topoisomerase 2 inhibitor treatment downregulates Alt-NHEJ repair pathway proteins in cell lines and AML patient cells with FLT3-ITD, and markedly downregulates c-Myc. This evidence concerns the gene PIM1 and acute myeloid leukemia.